These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 22146979)

  • 21. Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss.
    Mori N; Kyo S; Sakaguchi J; Mizumoto Y; Ohno S; Maida Y; Hashimoto M; Takakura M; Inoue M
    Cancer Sci; 2007 Dec; 98(12):1881-8. PubMed ID: 17924977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
    Ogawa K; Sun C; Horii A
    Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIK3CA alterations in Middle Eastern ovarian cancers.
    Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
    Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.
    Myers AP; Filiaci VL; Zhang Y; Pearl M; Behbakht K; Makker V; Hanjani P; Zweizig S; Burke JJ; Downey G; Leslie KK; Van Hummelen P; Birrer MJ; Fleming GF
    Gynecol Oncol; 2016 Apr; 141(1):43-8. PubMed ID: 27016228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The associations of hub gene polymorphisms in PI3K/AKT/mTOR pathway and Schistosomiasis Japonica infection and hepatic fibrosis.
    Xiao Q; Yu H; Zhu X
    Infect Genet Evol; 2020 Nov; 85():104423. PubMed ID: 32554084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.
    Pande M; Bondy ML; Do KA; Sahin AA; Ying J; Mills GB; Thompson PA; Brewster AM
    Breast Cancer Res Treat; 2014 Sep; 147(2):381-7. PubMed ID: 25108739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
    Kim JG; Chae YS; Sohn SK; Kang BW; Moon JH; Lee SJ; Jeon SW; Park JS; Park JY; Choi GS
    Oncology; 2010; 79(3-4):278-82. PubMed ID: 21412012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
    Su CC
    Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.
    Nout RA; Bosse T; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; van Eijk R; Ter Haar NT; Smit VT
    Gynecol Oncol; 2012 Sep; 126(3):466-73. PubMed ID: 22609107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding.
    Painter JN; Kaufmann S; O'Mara TA; Hillman KM; Sivakumaran H; Darabi H; Cheng THT; Pearson J; Kazakoff S; Waddell N; Hoivik EA; Goode EL; Scott RJ; Tomlinson I; Dunning AM; Easton DF; French JD; Salvesen HB; Pollock PM; Thompson DJ; Spurdle AB; Edwards SL
    Am J Hum Genet; 2016 Jun; 98(6):1159-1169. PubMed ID: 27259051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
    Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F
    Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
    Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
    Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
    Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
    Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.
    Dienstmann R; Serpico D; Rodon J; Saura C; Macarulla T; Elez E; Alsina M; Capdevila J; Perez-Garcia J; Sánchez-Ollé G; Aura C; Prudkin L; Landolfi S; Hernández-Losa J; Vivancos A; Tabernero J
    Mol Cancer Ther; 2012 Sep; 11(9):2062-71. PubMed ID: 22723336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines.
    Riquelme I; Tapia O; Espinoza JA; Leal P; Buchegger K; Sandoval A; Bizama C; Araya JC; Peek RM; Roa JC
    Pathol Oncol Res; 2016 Oct; 22(4):797-805. PubMed ID: 27156070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
    Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
    PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
    Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
    Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.